The Coalition for Safe and Innovative Medicine
was founded to work toward creating a process for review and approval of safe and effective follow-on versions of revolutionary biologic medicine that:
- Maintains the current high scientific standards to ensure patient safety
- Preserves incentives for innovation; and
- Lowers consumer costs
We believe Congress should create a process for approval of new biosimilars that lowers consumer costs while ensuring patient safety and preserving incentives for innovation.
We support legislation currently being considered by Congress that would establish a safe and secure process for developing less expensive versions of complex biologic drugs.
We oppose a legislative approach that would lower standards of patient safety and undermine confidence in this life-altering field of new medicines by not ensuring these drugs are independently tested for safety and efficacy.